Lucas C P, Morledge J H, Tessman D K
Clin Ther. 1985;8(1):49-60.
The added hypotensive effect of bevantolol, a new cardioselective beta-blocker, was studied in 244 patients with mild to moderate essential hypertension following prior treatment with hydrochlorothiazide or placebo. After four weeks of monotherapy with 50 mg/day or 100 mg/day of hydrochlorothiazide or placebo, the mean diastolic blood pressure of the patients in these groups decreased from baseline by 8.6, 8.8, and 4.3 mmHg, respectively. During the subsequent four weeks of dual therapy with 400 mg/day of bevantolol added to the regimen, additional and uniform mean decreases of 7.5, 7.3, and 7.5 mmHg occurred, providing total mean diastolic pressure decreases from baseline of 16.1, 16.1, and 11.8 mmHg in the three groups, respectively. These diastolic pressures were significantly lower during dual therapy than during monotherapy and lower in both diuretic groups than in the placebo group during monotherapy and dual therapy (P less than 0.001). Fewer adverse reactions occurred during dual therapy than during monotherapy. The addition of bevantolol to a thiazide diuretic regimen provided safe and significantly better control of mild to moderate hypertension than did the diuretic alone.
对244例轻度至中度原发性高血压患者进行了研究，这些患者此前接受过氢氯噻嗪或安慰剂治疗，旨在探究新型心脏选择性β受体阻滞剂倍凡洛尔的附加降压效果。在用50mg/天或100mg/天的氢氯噻嗪或安慰剂进行四周单一疗法后，这些组患者的平均舒张压分别较基线水平降低了8.6、8.8和4.3mmHg。在随后四周的联合疗法中，即在治疗方案中添加400mg/天的倍凡洛尔，三组患者的平均舒张压又分别额外均匀降低了7.5、7.3和7.5mmHg，三组患者的平均舒张压较基线水平总共分别降低了16.1、16.1和11.8mmHg。联合疗法期间的舒张压显著低于单一疗法期间，且在单一疗法和联合疗法期间，两个利尿剂组的舒张压均低于安慰剂组（P<0.001）。联合疗法期间发生的不良反应少于单一疗法期间。在噻嗪类利尿剂治疗方案中添加倍凡洛尔，与单独使用利尿剂相比，能更安全且显著更好地控制轻度至中度高血压。
